ACMJ
Anatolian Current Medical Journal

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2718-0115
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
The relationship between melatonin level, oxidative stress, fatigue and sleep disorders in multiple sclerosis patients
Abstract
Aims: Our study aimed to investigate the relationship between oxidative stress and melatonin levels, sleep disturbances and fatigue in persons with MS (pwMS).
Methods: The study included 50 pwMS and 30 healthy controls. Levels of serum melatonin, glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) were measured in both groups. Persons with MS (pwMS) were evaluated using the extended disability status scale (EDDS) while Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale, insomnia severity index, fatigue severity scale and Beck depression scale were used for both groups.
Results: Persons with MS (pwMS) exhibited significantly higher sleep disturbances (p<0,001), PSQI score (p<0,001), sleep latency (p=0,014), insomnia severity (p=0,001), fatigue (0,001) and fatigue severity (p<0,001), and Beck depression scale scores (p<0,001) and SOD levels (p<0,001) compared to the control group, while exhibiting significantly lower levels of melatonin(p=0,004). In pwMS, patients who experienced difficulty sleeping had significantly lower melatonin levels compared to those who did not (p=0,049). In pwMS, the melatonin level showed a negative correlation with age (r=-0,341; p=0,015) and EDSS (r=-0,386; p=0,006). Persons with MS (pwMS) with fatigue had significantly higher EDSS (p=0,003), PUQI (p=0,001), Epworth sleepiness score (p=0,028) and insomnia scores (p=0,002), compared to those who didn’t.
Conclusion: Our results showed that the melatonin levels were lower, presence of fatigue, and fatigue severity were higher in pwMS with sleep disorders than in those without sleep disorders. The frequent occurrence of fatigue(indirectly) and sleep disturbances in pwMS can be attributed to low melatonin levels.

Keywords : Multiple sclerosis, melatonin, sleep disturbances, oxidative stress, fatigue

Download Article


1. Comabella M, Khoury SJ. Immunopathogenesis of multiplesclerosis. Clin Immunol. 2012;142(1):2-8.
2. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis:current knowledge and future outlook. Eur Neurol. 2014;72(3-4):132-141.
3. Golan D, Staun-Ram E, Glass-Marmor L, et al. The influence ofvitamin D supplementation on melatonin status in patients withmultiple sclerosis. Brain Behav Immun. 2013;32:180-185.
4. Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stressin the pathogenesis of multiple sclerosis: the need for effectiveantioxidant therapy. J Neurol. 2004;251(3):261-268.
5. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX.Melatonin: an established antioxidant worthy of use in clinicaltrials. Mol Med. 2009;15(1):43-50.
6. Cote I, Trojan DA, Kaminska M, et al. Impact of sleepdisorder treatment on fatigue in multiple sclerosis. Mult Scler.2013;19(4):480-489.
7. Hagan RM, Oakley NR. Melatonin comes of age? TrendsPharmacol Sci. 1995;16(3):81-83.
8. Kurtzke JF. Rating neurologic impairment in multiplesclerosis: an expanded disability status scale (EDSS). Neurol.1983;33(11):1444-1452.
9. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigueseverity scale: application to patients with multiple sclerosis andsystemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123.
10. Agargun M. Pittsburgh uyku kalitesi indeksinin gecerligi veguvenirligi. Turk Psikiyatri Derg. 1996;7:107-115.
11. Izci B, Ardic S, Firat H, Sahin A, Altinors M, Karacan I. Reliabilityand validity studies of the Turkish version of the Epworthsleepiness scale. Sleep Breath. 2008;12(2):161-168.
12. Boysan M, G&uuml;le&ccedil; M, Besiroglu L, Kalafat T. Uykusuzluk şiddetiindeksi&rsquo;nin T&uuml;rk &ouml;rneklemindeki psikometrik &ouml;zellikleri.Anadolu Psikiyatri Derg. 2010;11(3):248-252.
13. Hisli N. Beck Depresyon envanterinin gecerliligi uzerine bitcalisma (a study on the validity of Beck depression inventory.).Psikol Derg. 1988;6:118-122.
14. Anisimov VN, Popovich IG, Zabezhinski MA, Anisimov SV,Vesnushkin GM, Vinogradova IA. Melatonin as antioxidant,geroprotector and anticarcinogen. Biochim Biophys Acta. 2006;1757(5-6):573-589.
15. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animaltissues by thiobarbituric acid reaction. Anal Biochem. 1979;95(2):351-358.
16. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, PalasodkarR. Oxidative damage and major depression: the potentialantioxidant action of selective serotonin re-uptake inhibitors.Redox Rep. 2003;8(6):365-370.
17. Smolders J, Peelen E, Thewissen M, et al. The relevance ofvitamin D receptor gene polymorphisms for vitamin D researchin multiple sclerosis. Autoimmun Rev. 2009;8(7):621-626.
18. Sakkas GK, Giannaki CD, Karatzaferi C, Manconi M. Sleepabnormalities in multiple sclerosis. Curr Treat Options Neurol.2019;21(1):4.
19. Haider L, Fischer MT, Frischer JM, et al. Oxidative damage inmultiple sclerosis lesions. Brain. 2011;134(7):1914-1924.
20. Ferretti G, Bacchetti T. Peroxidation of lipoproteins in multiplesclerosis. J Neurol Sci. 2011;311(1-2):92-97.
21. Adamczyk-Sowa M, Sowa P, Pierzchala K, Polaniak R, Labuz-Roszak B. Antioxidative enzymes activity and malondialdehydeconcentration during mitoxantrone therapy in multiple sclerosispatients. J Physiol Pharmacol. 2012;63(6):683-690.
22. Tasset I, Ag&uuml;era E, S&aacute;nchez-L&oacute;pez F, et al. Peripheral oxidativestress in relapsing-remitting multiple sclerosis. Clin Biochem.2012;45(6):440-444.
23. Hedstr&ouml;m AK, &Aring;kerstedt T, Hillert J, Olsson T, Alfredsson L. Shiftwork at young age is associated with increased risk for multiplesclerosis. Ann Neurol. 2011;70(5):733-741.
24. Adamczyk-Sowa M, Pierzchala K, Sowa P, Polaniak R, KuklaM, Hartel M. Influence of melatonin supplementation on serumantioxidative properties and impact of the quality of life inmultiple sclerosis patients. J Physiol Pharmacol. 2014;65(4):543-550.
25. McCord JM. Human disease, free radicals, and the oxidant/antioxidant balance. Clin Biochem. 1993;26(5):351-357.
26. Kostoglou-Athanassiou I. Therapeutic applications of melatonin.Ther Adv Endocrinol Metab. 2013;4(1):13-24.
27. Wurtman RJ, Zhdanova I. Improvement of sleep quality bymelatonin. Lancet. 1995;346(8988):1491.
28. Ebers GC. Environmental factors and multiple sclerosis. LancetNeurol. 2008;7(3):268-277.
29. Emre U, Erg&uuml;n U, Yıldız H, Coşkun &Ouml;, İnan L. Multipl sklerozdadepresyon. D&uuml;ş&uuml;nen Adam. 2003;16(1):53-56.
Article available in :
Volume 6, Issue 2, 2024
Page : 168-174
https://doi.org/10.38053/acmj.1395276
Article Information
Submitted : 24 Kas 2023
Accepted : 19 Şub 2024
Corresponding Author :

Yıldız Dağcı: Department of Neurology, Erzurum City Hospital, Erzurum, Turkiye

[email protected]
Citation : Dağcı Y, Bilge N, Ceylan M, Özkan Hİ. The relationship between melatonin level, oxidative stress, fatigue and sleep disorders in multiple sclerosis patients. Anatolian Curr Med J. 2024;6(2):168-174.

Read: 28
Cited: 0
Download : 12
_Footer